Femasys (FEMY) Expected to Announce Earnings on Wednesday

Femasys (NASDAQ:FEMY) is projected to issue its Q2 2026 results before the market opens on Wednesday, August 12th. Analysts expect the company to announce earnings of ($1.2667) per share and revenue of $0.7310 million for the quarter. Parties may visit the the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Friday, August 14, 2026 at 4:00 PM ET.

Femasys (NASDAQ:FEMY) last announced its quarterly earnings data on Friday, May 8th. The company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.33) by $1.43. The company had revenue of $0.42 million for the quarter, compared to the consensus estimate of $0.77 million. Femasys had a negative return on equity of 258.08% and a negative net margin of 521.97%.

Femasys Stock Up 2.7%

Shares of NASDAQ:FEMY opened at $3.05 on Wednesday. Femasys has a 1 year low of $2.64 and a 1 year high of $22.20. The company has a debt-to-equity ratio of 0.53, a current ratio of 3.91 and a quick ratio of 1.98. The business’s 50-day moving average is $4.36 and its 200-day moving average is $7.86. The company has a market capitalization of $9.21 million, a price-to-earnings ratio of -0.56 and a beta of -2.08.

Institutional Trading of Femasys

Several large investors have recently made changes to their positions in the company. Kovack Advisors Inc. acquired a new position in Femasys during the 4th quarter worth approximately $27,000. HRT Financial LP acquired a new position in shares of Femasys during the fourth quarter worth approximately $30,000. Cetera Investment Advisers bought a new position in shares of Femasys in the 4th quarter worth $36,000. Osaic Holdings Inc. acquired a new stake in Femasys in the 2nd quarter valued at $45,000. Finally, State Street Corp increased its stake in Femasys by 43.5% during the 4th quarter. State Street Corp now owns 80,869 shares of the company’s stock valued at $47,000 after purchasing an additional 24,500 shares in the last quarter. 65.27% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have issued reports on the company. Wall Street Zen raised Femasys to a “hold” rating in a research note on Saturday, June 13th. Weiss Ratings raised shares of Femasys from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $106.67.

About Femasys

Femasys International, Inc is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women’s health applications. The company’s core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care.

The company’s flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography.